AR065377A1 - Derivados de 4, 5, 6, 7-tetrahidro-pirazolo[3, 4-c]piridina, composiciones farmaceuticas que los comprenden y su uso para tratar enfermedades mediadas por la actividad de la catepsina s. - Google Patents
Derivados de 4, 5, 6, 7-tetrahidro-pirazolo[3, 4-c]piridina, composiciones farmaceuticas que los comprenden y su uso para tratar enfermedades mediadas por la actividad de la catepsina s.Info
- Publication number
- AR065377A1 AR065377A1 ARP080100663A ARP080100663A AR065377A1 AR 065377 A1 AR065377 A1 AR 065377A1 AR P080100663 A ARP080100663 A AR P080100663A AR P080100663 A ARP080100663 A AR P080100663A AR 065377 A1 AR065377 A1 AR 065377A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- 4alkyl
- substituted
- group
- phenyl
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 46
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 125000005843 halogen group Chemical group 0.000 abstract 17
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 13
- 125000001424 substituent group Chemical group 0.000 abstract 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000002950 monocyclic group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- -1 CF 3 Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 108090000613 Cathepsin S Proteins 0.000 abstract 2
- 102100035654 Cathepsin S Human genes 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- PLDDTNKKLOTJCZ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-pyrazolo[4,3-b]pyridine Chemical class C1=CNC2CNNC2=C1 PLDDTNKKLOTJCZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 239000005977 Ethylene Chemical group 0.000 abstract 1
- 229910003813 NRa Inorganic materials 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen compuestos tetrahidro-pirazolo-piridina unidos a carbono, que son utiles como moduladores de catepsina S. Dichos compuestos pueden utilizarse en composiciones farmacéuticas y para el tratamiento de afeccion médicas, trastornos, ypatologías mediadas por la actividad de catepsina S, tales como psoriasis, dolor, esclerosis multiple, aterosclerosis, y artritis reumatoide. Reivindicacion 1: Un compuesto de Formula (1): donde: R1 y R2 tomados junto con el átomo de nitrogeno alque están unidos forman un grupo heterocicloalquilo monociclico saturado, cada grupo contiene opcionalmente un miembro adicional de un anillo heteroátomo que es O, S, o NRa, y cada grupo no está sustituido o se sustituye con uno, dos o tressustituyentes Rb; donde Ra es H, alquilo C1-4, -COalquilo C1-4, -CO(fenilo), o -CO2alquilo C1-4, o un anillo cicloalquilo monocíclico, anillo fenilo, o anillo heteroarilo monocíclico, cada anillo no está sustituido o se sustituye con OH, alquilo C1-4, CF3, halo,-Oalquilo C1-4, ciano, o -COalquilo C1-4; y cada sustituyente Rb es independientemente: i) OH, alquilo C1-4, -alquil C1-4-OH, CF3, NRcRd, halo, -Oalquilo C1-4, -COalquilo C1-4, -CO2aIquilo C1-4, -CO2H, o CONReRf; ii) un grupoheterocicloalquilo monocíclico no sustituido o sustituido con alquilo C1-4, -COalquilo C1-4, -CO2alquilo C1-4, OH, -Oalquilo C1-4, NRcRd, o halo; iii) un grupo heterocicloalquilo monocíclico fusionado con un grupo fenilo o piridilo, el grupobicíclico fusionado resultante no está sustituido o se sustituye con alquilo C1-4, OH, -Oalquilo C1-4, NRcRd, o halo; o iv) un grupo fenilo o un grupo heteroarilo monociclico, cada grupo no está sustituido o se sustituye con alquilo C1-4, OH, -Oalquilo C1-4, NRcRd, o halo; o v) dos sustituyentes Rb en el mismo carbono tomados junto con el carbono al que están unidos forman un grupo heterocicloalquilo monociclico saturado, no sustituido o sustituido con alquilo C1-4, OH, -Oalquilo C1-4,NRcRd, o halo: vi) dos sustituyentes Rb forman un puente metileno o etileno; o vii) dos sustituyentes Rb en carbonos contiguos tomados junto con los carbonos a los que están unidos forman un grupo cicloalquilo monociclico saturado o grupoheterocicloalquilo monocíclico saturado, cada grupo no está sustituido o se sustituye con alquilo C1-4, OH, -Oalquilo C1-4, NRcRd, o halo; donde Rc es H o alquilo C1-4; Rd es H, alquilo C1-4, -COalquilo C1-4, -COalquil C1-4-OH, -CO2alquilo C1-4,-CONRxRy, o -SO2alquilo C1-4; donde Rx y Ry son cada uno independientemente H o alquilo C1-4; y Re y Rf son cada uno independientemente H o alquilo C1-4; R3 es H, OH, alquilo C1-4, o -Oalquilo C1-4; R4 es H; alquilo C1-4; -COalquilo C1-4 nosustituido o sustituido con OH, F, -OCOalquilo C1-4, o NRtRu; -COCF3 -CO-(heteroarilo monocíclico); -CO(heterocicloalquilo monocíclico unido a C); -CO-(fenilo): -SO2alquilo C1-4; -SO2CF3; SO2NRtRu; -CONRtRu; -COCO2alquilo C1-4 o -COCONRtRu: donde Rty Ru son cada uno independientemente H, alquilo C1-4, o -COalquilo C1-4 o Rt y Ru tomados junto con el nitrogeno al que están unidos forman un anillo heterocicloalquilo monocíclico; R5 es halo o CF3; cada R6 es independientemente H o F; D es -CEC-R7, -CH=CH-R8, -(CH2)2-3-R8, o -(CH2)3-5-R9; donde R7 es: I) un grupo alquilo C1-4 no sustituido o sustituido con OH, -Oalquilo C1-4, -NRgRh, fenilo, o fenoxi, cada fenilo o fenoxi no está sustituido o se sustituye con alquilo C1-4, OH, -Oalquilo C1-4, halo, o CF3 donde Rg y Rh son cada uno independientemente H, alquilo C1-4, -COalquilo C1-4, -COfenilo, -CO2alquilo C1-4, -SO2alquilo C1-4, o -SO2-fenilo; o Rg y Rh tomados junto con el nitrogeno al que están unidos forman un grupoheterocicloalquilo monociclico; o II) un grupo cicloalquilo monociclico, grupo fenilo o grupo heteroarilo monociclico, cada grupo no está sustituido o se sustituye con uno o dos sustituyentes Rk; donde R8 es un grupo fenilo o un grupo heteroarilomonociclico, cada grupo no está sustituido o se sustituye con uno o dos sustituyentes Rk; donde R9 es OH o -NRnRo; donde Rn es H o alquilo C1-4; y Ro es H, alquilo C1-4, cicloalquilo monociclico, -COalquilo C1-4, -COfenilo, -CO2alquilo C1-4, -SO2aIquilo C1-4, -SO2-fenilo, -SO2-bencilo, o -SO2NRpRq, cada grupo fenilo o bencilo no está sustituido o se sustituye con uno o dos sustituyentes Rk; donde Rp y Rq son cada uno independientemente H o alquilo C1-4; o Rn y Ro tomados junto con elnitrogeno al que están unidos forman un anillo heterocicloalquilo monociclico saturado no sustituido o sustituido con alquilo C1-4, OH, -Oalquilo C1-4, halo, o CF3; donde cada sustituyente Rk en D es independientemente: a) un grupo alquilo C1-4 nosustituido o sustituido con OH. -Oalquilo C1-4, - OalquilC1-4-OH, halo, -CO2alquilo C1-4, CO2H, CN, NRrRs, -N(Rr)CO-fenilo, N(Rr)SO2alquilo C1-4, N(Rr)SO2fenilo, -SO2alquilo C1-4, fenilo, o fenoxi; b) un sustituyente de formula (2)donde cada Rv esindependientemente H o alquilo C1-4, o ambos sustituyentes Rv forman juntos un carbonilo; Rw es H, alquilo C1-4, -CH2OH, o -CO2alquilo C1-4; A es O o NRaa; donde Raa es H o alquilo C1-4 y Z es un grupo fenilo, grupo bencilo, grupo cicloalquilo,grupo heterocicloalquilo, grupo heteroarilo, o grupo -CH2-(heteroarilo), cada grupo no está sustituido o se sustituye con uno o dos sustituyentes independientemente seleccionados del grupo que consiste en alquilo C1-4, CF3, halo, OH, -Oalquilo C1-4,-OCF3, -OCHF2, NRddRee, -CO2alquilo C1-4, -Salquilo C1-4, y -SO2alquilo C1-4; donde Rdd y Ree son cada uno independientemente H o alquilo C1-4; c) dos sustituyentes Rk contiguos tomados junto con los carbonos a los que están unidos forman un anillofenilo, anillo heteroarilo monociclico, anillo heterocicloalquilo monociclico, o anillo cicloalquilo monociclico fusionado, cada anillo fusionado no está sustituido o se sustituye con: alquilo C1-4, -alquil C1-4-CF3 -alquilo C1-4-OH, -alquil C1-4CO2alquilo C1-4, CF3, alquenilo C2-4, halo, OH, -Oalquilo C1-4, -COalquilo C1-4, -COCF3, -CO2alquilo C1-4, -CO2H, -CONRffRgg o -SO2alquilo C1-4 o con un grupo cicloalquilo, grupo -CH2-(cicloalquilo), o grupo bencilo, cada grupo no está sustituido ose sustituye con alquilo C1-4, OH, -Oalquilo C1-4, halo, o CF3; donde Rff y Rgg son cada uno independientemente H o alquilo C1-4, o Rff y Rgg tomados junto con el nitrogeno al que están unidos forman un anillo heterocicloalquilo monociclico, nosustituido o sustituido con alquilo C1-4 o OH; o d) OH; -Oalquilo C1-4; halo; CF3 -CHO; -CO2alquilo C1-4 CO2H; CN; -NO2 -CONRrRs, NRrRs; -N(Rr)-fenilo; -N(Rr)-bencilo; -N(Rr)-fenetilo; -N(Rr)COalquilo C1-4; -N(Rr)CO-fenilo; -N(Rr)SO2alquilo C1-4 -N(Rr)SO2-fenilo; -SO2alquilo C1-4 fenoxi; o un grupo heteroarilo; donde cada grupo fenilo, bencilo, fenetilo, fenoxi, o heteroarilo no está sustituido o se sustituye con alquilo C1-4, OH, -Oalquilo C1-4, halo, o CF3 donde Rr es H, alquilo C1-4,alquil C2-4-OH; y Rs es H, alquilo C1-4, -alquil C1-4-CF3, -alquil C1-4-CN, -alquil C2-4-OH, -alquil C2-4-NRbbRcc, -alquil C1-4CO2alquilo C1-4, -alquil C1-4CO2H, alquenilo C3-4, - COalquilo C1-4, o CO2alquilo C1-4 donde Rbb es H o alquilo C1-4 y;Rcc es H, alquilo C1-4, -COalquilo C1-4, o -CO2alquilo C1-4; o Rbb y Rcc tomados junto con el nitrogeno al que están unidos forman un anillo heterocicloalquilo monociclico; o Rr y Rs tomados junto con el nitrogeno al que están unidos forman un grupoheterocicloalquilo no sustituido o sustituido con alquilo C1-4, OH, -Oalquilo C1-4, halo, CF3, o un anillo heterocicloalquilo monociclico no sustituido o sustituido con OH; o una sal aceptable para uso farmacéutico, profármaco, o metabolito delmismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88997707P | 2007-02-15 | 2007-02-15 | |
| US12/031,010 US20080200454A1 (en) | 2007-02-15 | 2008-02-14 | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065377A1 true AR065377A1 (es) | 2009-06-03 |
Family
ID=39512608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100663A AR065377A1 (es) | 2007-02-15 | 2008-02-15 | Derivados de 4, 5, 6, 7-tetrahidro-pirazolo[3, 4-c]piridina, composiciones farmaceuticas que los comprenden y su uso para tratar enfermedades mediadas por la actividad de la catepsina s. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080200454A1 (es) |
| AR (1) | AR065377A1 (es) |
| CL (1) | CL2008000495A1 (es) |
| PA (1) | PA8769601A1 (es) |
| PE (1) | PE20090162A1 (es) |
| TW (1) | TW200843743A (es) |
| UY (1) | UY30921A1 (es) |
| WO (1) | WO2008100618A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009102937A1 (en) * | 2008-02-14 | 2009-08-20 | Sunesis Pharmaceuticals, Inc. | Processes for the preparation of carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US8895497B2 (en) * | 2009-12-04 | 2014-11-25 | Dcb-Usa, Llc | Cathepsin S inhibitors |
| WO2011094890A1 (en) * | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| CA2802733C (en) * | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| WO2012071186A1 (en) * | 2010-11-24 | 2012-05-31 | Allergan, Inc. | Modulators of s1p receptors |
| AU2016275764B8 (en) | 2015-06-11 | 2021-03-04 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| CN106916094B (zh) * | 2017-01-11 | 2019-06-04 | 青岛昌泰和生物科技有限公司 | 一种吲哚二酮化合物的制备方法 |
| WO2019074241A1 (ko) * | 2017-10-11 | 2019-04-18 | 정원혁 | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 |
| EP3946332A1 (en) | 2019-04-05 | 2022-02-09 | Université de Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2262674T3 (es) * | 2000-08-14 | 2006-12-01 | Ortho-Mcneil Pharmaceutical, Inc. | Pirazoles sustituidos. |
| NZ524193A (en) * | 2000-08-14 | 2004-12-24 | Ortho Mcneil Pharm Inc | Substituted pyrazoles |
| US7332494B2 (en) * | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
| US20050101587A9 (en) * | 2000-08-14 | 2005-05-12 | Butler Christopher R. | Method for treating allergies using substituted pyrazoles |
| US20070105841A1 (en) * | 2000-08-14 | 2007-05-10 | Breitenbucher J G | Method for treating allergies using substituted pyrazoles |
| US20070117785A1 (en) * | 2000-08-14 | 2007-05-24 | Butler Christopher R | Substituted pyrazoles and methods of treatment with substituted pyrazoles |
| PT1309593E (pt) * | 2000-08-14 | 2006-08-31 | Ortho Mcneil Pharm Inc | Pirazoles substituidos |
| US6369032B1 (en) * | 2000-09-06 | 2002-04-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating allergies |
| ATE413878T1 (de) * | 2000-09-06 | 2008-11-15 | Ortho Mcneil Pharm Inc | Methode zum bekämpfen der allergien durch verwendung von substituierten pyrazolen |
| US20030144234A1 (en) * | 2001-08-30 | 2003-07-31 | Buxton Francis Paul | Methods for the treatment of chronic pain and compositions therefor |
| US20030073672A1 (en) * | 2001-09-05 | 2003-04-17 | Breitenbucher J. Guy | Method for treating allergies using substituted pyrazoles |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201977D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0304640D0 (en) * | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
| US7173051B2 (en) * | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
| US7326715B2 (en) * | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7687515B2 (en) * | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
-
2008
- 2008-02-14 US US12/031,010 patent/US20080200454A1/en not_active Abandoned
- 2008-02-15 UY UY30921A patent/UY30921A1/es unknown
- 2008-02-15 AR ARP080100663A patent/AR065377A1/es not_active Application Discontinuation
- 2008-02-15 CL CL2008000495A patent/CL2008000495A1/es unknown
- 2008-02-15 WO PCT/US2008/002108 patent/WO2008100618A2/en not_active Ceased
- 2008-02-15 PA PA20088769601A patent/PA8769601A1/es unknown
- 2008-02-15 TW TW097105280A patent/TW200843743A/zh unknown
- 2008-02-15 PE PE2008000334A patent/PE20090162A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008000495A1 (es) | 2008-11-03 |
| UY30921A1 (es) | 2008-09-02 |
| WO2008100618A2 (en) | 2008-08-21 |
| WO2008100618A3 (en) | 2008-10-02 |
| PA8769601A1 (es) | 2009-03-31 |
| TW200843743A (en) | 2008-11-16 |
| US20080200454A1 (en) | 2008-08-21 |
| PE20090162A1 (es) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065377A1 (es) | Derivados de 4, 5, 6, 7-tetrahidro-pirazolo[3, 4-c]piridina, composiciones farmaceuticas que los comprenden y su uso para tratar enfermedades mediadas por la actividad de la catepsina s. | |
| IL277183B2 (en) | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation | |
| JP2007532651A5 (es) | ||
| RU2012157293A (ru) | Макроциклические соединения, применимые в качестве ингибиторов гистондеацетилаз | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| AR056404A1 (es) | N-heteroarilpiperazinil ureas como moduladoras de la amida hidrolasa del acido graso y composicion farmaceutica | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
| AR068145A1 (es) | 2- (fenil sustituido )-6-amino-5-alcoxi, tiolcoxi y aminoalquil-4- pirimidina carboxilatos, sus usos como herbicidas y composicion herbicida | |
| HRP20220885T1 (hr) | Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| JP2014506599A5 (es) | ||
| HRP20150543T1 (hr) | Međuprodukti za pripravu halikondrina b | |
| SI2736887T1 (en) | Hydrazide containing nuclear transport modulators and uses thereof | |
| AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
| AR085502A1 (es) | Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen | |
| AR080189A2 (es) | Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de la replicacion del vhc | |
| HRP20130900T1 (hr) | Derivat (aza)indola i njegova uporaba u medicinske svrhe | |
| IL264982B (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| JP2010536887A5 (es) | ||
| HRP20130738T1 (hr) | Postupak lijeäśenja ili profilakse | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| AR101265A1 (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |